Placeholder Banner

Cures Acceleration Network: BIO Strongly Supports the CAN Program

March 10, 2016

On behalf of the Biotechnology Industry Organization (BIO), I am writing to express our strong support for $500 million for Cures Acceleration Network (CAN) Act, a new initiative at the National Industries of Health (NIH) that was authorized in the recently-enacted Patient Protections and Afforadable Care Act.

Download Full Comments Below
FY 2011 CAN Letter (Senate) 0
Read BIO’s letter to the Senate Appropriations Committee
Discover More
The Biotechnology Innovation Organization (BIO) is pleased to respond to the U.S. Department of Agriculture’s (USDA) Solicitation of Input from Stakeholders on Agricultural Innovations. BIO applauds USDA for taking a proactive approach and seeking…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or…